同型半氨酸和外围白细胞计数衍生的比率:从健康人口的见解
Pawar Neelam1, Kollampare Sowndarya1, Hegde Anupama1
1Department of Biochemistry, Kasturba Medical College Mangalore, Manipal Academy of Higher Education, Manipal, India.
Advanced biomedical research
|February 11, 2026
概括
高homocysteine (高homocysteinemia) 影响健康个体的白细胞计数. 这项研究发现,高homocysteinemia与周围血液细胞比率的显著变化有关.
科学领域:
- 心血管研究研究心血管研究
- 血液学 血液学 血液学
- 生物标志物发现发现
背景情况:
- 同型氨酸 (Hcy) 和脂质失调是动脉样硬化的主要危险因素.
- 作为潜在的生物标志物,外围血液细胞 (PBC) 的比例正在被探索.
- 之前的研究将白细胞 (WBC) 数与各种健康指标联系起来.
研究的目的:
- 在健康个体中研究PBC衍生比率与Hcy水平之间的关联.
- 探索PBC衍生的比率和脂质参数之间的关系.
- 为了确定潜在的基于血液的生物标志物对心血管风险.
主要方法:
- 从残留样本评估Hcy水平,并从实验室信息系统 (LIS) 检索脂质谱和白细胞计数.
- 计算了各种PBC衍生的比率,包括中性细胞与淋巴细胞的比率 (NLR),淋巴细胞与单细胞的比率 (LMR),单细胞与HDL的比率 (MHR) 和淋巴细胞与HDL的比率 (LHR).
- 采用双变异相关性来分析Hcy,脂质资料和PBC衍生的比率之间的关联.
主要成果:
- 超homocysteinemia (HHcy) 是普遍存在的 (43.54%) 和显著与增加的埃索因菲尔 (P=0.019) 相关.
- 在HHcy中观察到脱脂症和改变的PBC衍生的比率,尽管在统计学上不显著.
- 在中性粒细胞和正常Hcy (NHcy) 水平 (r=-0.346,P=0.042) 之间,以及在乙酸/基酸和HHcy之间 (分别r=-0.476,P=0.013和r=-0.575,P=0.002) 发现了显著的负相关性.
结论:
- 超同胞蛋白血症与周围血液细胞计数的显著变化有关.
- 来自PBC的比率可以作为与Hcy水平和心血管风险相关的指标.
- 需要进一步的研究来验证这些发现及其临床影响.
相关概念视频
Conservation of Small Populations
17.4K
Small population sizes put a species at extreme risk of extinction due to a lack of variation, and a consequent decrease in adaptability. This weakens the chances of survival under pressures such as climate change, competition from other species, or new diseases. Large populations are more likely to survive pressures such as these, as such populations are more likely to harbor individuals that have genetic variants that are adaptive under new stresses. Small populations are much less...
17.4K
What is Population Genetics?
65.0K
A population is composed of members of the same species that simultaneously live and interact in the same area. When individuals in a population breed, they pass down their genes to their offspring. Many of these genes are polymorphic, meaning that they occur in multiple variants. Such variations of a gene are referred to as alleles. The collective set of all the alleles within a population is known as the gene pool.
65.0K
Population Growth
28.7K
Population size is dynamic, increasing with birth rates and immigration, and decreasing with death rates and emigration. In ideal conditions with unlimited resources, populations can increase exponentially, which plots as a J-shaped growth rate curve of population size against time. This type of curve is characteristic of newly-introduced invasive species, or populations that have suffered catastrophic declines and are rebounding.
28.7K
Poisson's Ratio
1.2K
Poisson's ratio is a material property that indicates their stress response. It explains the connection between the elongation or compression a material undergoes in the direction of an applied force and the contraction or expansion it experiences perpendicular to that force. When a slender bar is loaded axially, it stretches in the direction of the force and contracts laterally. Poisson's ratio is the negative ratio of this lateral contraction to the axial elongation. The negative sign...
1.2K
Odds Ratio
1.9K
The odds ratio (OR) is a statistical measure used extensively in epidemiology and research to quantify the strength of association between exposure and outcome across different groups. Unlike relative risk, which compares the probabilities of an event occurring, the odds ratio compares the odds of an event occurring in the exposed group to the odds of it occurring in the unexposed group. The odds, in this context, are calculated as the probability of the event happening divided by the...
1.9K
Hazard Ratio
624
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
624


